Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
132 hedge funds and large institutions have $382M invested in Array Biopharma Inc in 2016 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 43 increasing their positions, 42 reducing their positions, and 34 closing their positions.
2% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 42
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less call options, than puts
Call options by funds: $5.4M | Put options by funds: $5.87M
13% less funds holding
Funds holding: 151 → 132 (-19)
34% less capital invested
Capital invested by funds: $578M → $382M (-$195M)
50% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$6.52M |
| 2 |
AC
Armistice Capital
New York
|
+$5.99M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$3.9M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$3.5M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$2.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.8M |
| 2 |
Millennium Management
New York
|
-$11.1M |
| 3 |
First Manhattan
New York
|
-$4.64M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$4.46M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.02M |
ARRY Hedge Fund Activity: Q1 2016 in Review
132 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q1 2016, worth a combined $382M — down 34% from $578M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of ARRY and 17 opened new positions — a net loss of 17 holders — while 42 trimmed existing stakes and 43 added.
The largest buyer was Sarissa Capital Management, adding an estimated $6.52M. The largest seller was Fidelity Investments, cutting an estimated $15.8M.
- 132 institutional investors held Array Biopharma Inc (ARRY) as of Q1 2016, down from 151 in Q4 2015.
- Funds reported $382M of Array Biopharma Inc stock for Q1 2016, down 34% quarter-over-quarter.
- 17 funds opened new Array Biopharma Inc positions in Q1 2016 and 34 closed out, a net change of -17 holders.
- The largest Array Biopharma Inc buyer in Q1 2016 was Sarissa Capital Management, an estimated $6.52M added.
- The largest Array Biopharma Inc seller in Q1 2016 was Fidelity Investments, an estimated $15.8M sold.
Based on aggregated 13F filings for Q1 2016.